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Abstract
Background: Immune checkpoint inhibitors (ICI) target T cell inhibitory pathways that are responsible for cancer
tolerance by down-modulating immune functions. ICI have revolutionized patients care with lung cancer. Nevertheless,
restoring endogenous antitumor T-cell responses can induce immune related adverse events, such as sarcoidosis.
Case presentation: We report here the first case of a thoracic and cutaneous sarcoid-like reaction in a patient with a
relapsing unresectable non-small cell lung cancer (NSCLC) treated with nivolumab, an anti-PD-1 mAb. The expression
of PD-1 and its ligands, PD-L1 and PD-L2, was assessed by flow cytometry on peripheral blood mononuclear cells
(PBMC) and compared to patients who had discontinued nivolumab therapy without having developed any immune
related adverse events. PD-L1 expression was transiently increased on B cells, T cells and monocytes, whereas PD-L2
expression was not modulated. PD-1 was transiently undetectable when PD-L1 was maximal, before returning to basal
level. Sarcoidosis spontaneously resolved, without corticotherapy.
Conclusion: This case sheds the light on a complex regulation of PD-L1 expression in vivo on PBMC after nivolumab
arrest and triggers the question of monitoring the expression of immune checkpoint on immune cells during and after
treatment with ICI.
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Background
Lung cancer is the first and second cause of cancer mor-
tality in men and women, respectively, thus representing
an important health problem that needs new therapeutic
solutions. Immune checkpoint inhibitors (ICI), consisting
in neutralizing antibodies (Ab) targeting co-inhibitory
molecules to restore T cell activation, have revolutionized
cancer therapy. Anti-PD-1 Abs have emerged as powerful
weapons. Durable objective responses following anti-PD1
Ab therapy in patients with non-small-cell lung cancer
(NSLC), accompanied by extended overall survival
compared with conventional therapies, supported recent
regulatory approvals by the US Food and Drug Adminis-
tration for the use of nivolumab and pembrolizumab, two
different anti-PD1 Abs, in these indications. Nevertheless,
patients treated with ICI can develop immune related
adverse events, such as dermatological toxicities, as a
consequence of counteracting T cell inhibition. We report
here a case of sarcoidosis in a 56-year-old patient with
unresectable NSLC and treated with nivolumab.
PD-1 and PD-1 ligands expression was assessed on
peripheral blood mononuclear cells (PBMC) of the patient,
at different time-points (days 42, 56, 147 and 251)
after nivolumab arrest.* Correspondence: Jose.Hureaux@chu-angers.fr
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4Service de Pneumologie, Centre Hospitalier Universitaire, 4 rue Larrey, 49000
Angers, France
5MINT, Université d’Angers, UMR INSERM 1066 CNRS 6021, Angers, France
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Paolini et al. Journal for ImmunoTherapy of Cancer  (2018) 6:52 
https://doi.org/10.1186/s40425-018-0372-4
Case presentation
Nivolumab was initiated to treat a 56-year-old woman, with
unresectable NSCLC who initially received an adjuvant
chemotherapy consisting of 4 cycles of cisplatin-pemetrexed.
New lesions appeared and were classified pT3N0M0. Nivo-
lumab therapy was then initiated. Figure 1 summarizes the
key clinical and immunological data of the index case as well
as the timeline of immune checkpoint analysis.
No sign of SLR was detectable before the treatment
with nivolumab (Fig. 2a and f). A partial response was
observed after 5 infusions of nivolumab as suggested by
CT scan (Fig. 2b and g). Skin lesions appeared after 5
nivolumab infusions (Fig. 3), then mediastinal nodes size
started to increase and a micronodular interstitial
syndrome was observed (Fig. 2c and h) after 20 nivolumab
infusions. Biopsies showed epithelioid cells and Langhans
multinucleated giant cells without necrosis, microorgan-
isms or refringent bodies, compatible with sarcoid-like
inflammation (Fig. 3). Tumor cells, alcohol-acid resistant
bacilli and fungus or parasite were not detected
(data not shown). Nivolumab was then discontinued.
According to RECIST criteria, the patient had a partial
response at this time.
Mediastinoscopy revealed sarcoid lesions. Mediastinal
nodes sizes (Fig. 2d) and skin lesions were decreased
155 days later (data not shown), while the interstitial
syndrome had deteriorated (Fig. 2i). Bronchoalveolar lav-
age showed hypercellularity comprising 41% of lympho-
cytes without pathogens or cancer cells (data not
shown). 348 days later, CT scan showed normal medias-
tinal nodes and regression of the interstitial syndrome
(Fig. 2e and j).
The expression of PD-1, PD-L1 and PD-L2 was ana-
lyzed on PBMC at various time-points after stopping
nivolumab (defined as day 0). An important increase of
PD-L1 expression was observed on B and T cells at d56
with a peak at d147, compared to other patients treated
with nivolumab without relevant immune related reac-
tions (Fig. 4a). An elevated expression of PD-L1 was ob-
served on monocytes at d147 (Fig. 4a). PD-L1
expression by PBMC of the index case returned to basal
levels at d251 (Fig. 4a). If we hypothesize that the in-
crease of PD-L1 expression was consecutive to a re-
bound effect after stopping the treatment, we would
have observed a similar increase in patients treated with
nivolumab that did not exhibit immune related events.
Moreover, expression of PD-1 on T cells was punctually
undetectable at d147 at a time when PD-L1 expression
was maximal (Fig. 4b). No marked change of PD-L2 ex-
pression was observed. Intriguingly, the increased PD-L1
expression was evidenced only from day 56 to day 147
after nivolumab arrest (Fig. 4a). This observation sug-
gests that an elevated expression of PD-L1 consecutive
to blocking PD-1/PD-L1 interaction can be associated
with sarcoid-like reaction (SLR).
Discussion and concluding remarks
Immune checkpoint inhibitors have revolutionized the
therapeutic landscape in oncology. However, several
immune-related adverse events have been described, in-
cluding damages in skin, gastrointestinal tract, kidney
and nervous system. Among them, 11 cases of
sarcoidoisis-like syndroms have been reported during
melanoma treatment with ipilimumab, an anti-CTLA-4
Fig. 1 Timeline of clinical and biological analysis. Timeline reports the clinical signs of sarcoid-like reaction (upper part) and the biological
parameters (lower part) of the index case. Boxed numbers, time of analysis by flow cytometry of PD-1 and PD-L1 expression by PBMC of the
index case. WBC White blood cells; ACE Angiotensin converting enzyme
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mAb, used alone or in combination with nivolumab [1,
2]. More recently, studies reported that the inhibition of
the PD-1 / PD-1 L axis may also induce such adverse ef-
fects. Sarcoid development has also been reported in 2
melanoma patients treated with nivolumab [3, 4] and in
one melanoma patient treated with an anti-PD-L1 mAb
[5]. SLR were also reported in 3 sarcoma [6] and one
Hodgkin’s disease patient [7] treated with pembrolizu-
mab. In lung cancer, one study reported a case of sar-
coidosis with ipilumimab plus nivolumab [2]. A recent
publication reported nivolumab-related cutaneous
sarcoidosis in a patient with lung adenocarcinoma [8].
We report here the first case of thoracic and cutaneous
sarcoidosis in a patient with lung cancer and treated
with nivolumab.
To overcome the side effects of ICI, immunosup-
pressive drugs, such as steroids, are usually used for a
short period of time, with or without retracting ICI.
Interestingly, in this case, SLR resolved in the absence
of corticotherapy. In support, sarcoidosis spontan-
eously resolved in sarcoma patients treated with pem-
broluzimab [6].
Fig. 2 Measure of the size of mediastinal lymph nodes and interstitial syndrome. Plain chest computed tomography of the index case was
carried out at different time before and after treatment discontinuation. The mediastinal lymph nodes (white arrows) measurement was achieved
with a mediastinal-window setting (left panels, a-e) whereas interstitial syndrome was evaluated with a lung-window setting (right panels, f-j)
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Fig. 3 Histology of skin and lymph nodes lesions. Skin (upper panels, collected at the 5th nivolumab infusion) and thorax lymph nodes (lower
panels, collected at the 20th nivolumab infusion) were analyzed by immunohistochemistry (hematoxylin phloxine saffron staining). Left to right
panels, higher magnifications (scale bar, 400 μm). Black arrows correspond to lesions
Fig. 4 Analysis of PD-L1 and PD-1 expression on PBMC. PD-L1 (a) and PD-1 (b) expression was analyzed by flow cytometry on monocytes (CD14+
CD3− CD19−), B cells (CD19+ CD14− CD3−), CD4+ T cells (CD3+ CD4+ CD8− CD19− CD14−) and CD8+ T cells (CD3+ CD8+ CD4− CD19− CD14−)
from the index case and from control patients at different times after the nivolumab treatment was stopped. Results are expressed as relative
fluorescence intensity (RFI) defined as the ratio of specific fluorescence (median fluorescence of cells incubated with the anti-PD-L1 or anti-PD-1
Abs) over non-specific fluorescence (median fluorescence of cells incubated with the isotype control Ab). Each value from the time course
analysis of the patients is plotted. The grey area represents the 95% confidence interval of the level of PD-L1 or PD-1 expression on cells from 8
healthy subjects. Inserts, flow cytometry histograms for a representative control patient (left panels) and for the index case patient (right panels,
climax of the PD-L1 expression)
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It is interesting to note that the rapid decrease of
PD-L1 expression precedes the resolution of SLR. One
study has reported a local upregulation of PD-L1 expres-
sion in sarcoidosis and suggested that PD-1 blockade
could constitute a therapeutic target in sarcoidosis [9].
The increase of PD-L1 may also result from the unlock-
ing of cytokine production by activated T cells present in
sarcoid lesions as well as in the peripheral blood [10].
Indeed, restoring the functions of hyper-activated
TCRhigh, and especially the secretion of IFN-γ, may favor
sarcoidosis-like reaction [11].
Various lines of evidence support a role of the PD-1/
PD-L1 pathway in the prevention and downregulation of
SLR: (a) SLR can occur during anti-PD-1/PD-L1 and
-CTLA-4 Ab therapies [1, 2], (b) we and others [6] have
reported a favorable outcome after nivolumab discon-
tinuation without corticosteroid, (c) we report that
PD-L1 overexpression is concomitant with regression of
clinical and radiological signs of SLR and (d) PD-L1high
B cells have been shown to reduce inflammation [12].
Collectively, our observations suggest that a dysregulated
expression of PD-1 and PD-1 L is associated with
clinical signs of sarcoidosis-like syndromes.
In conclusion, this study evidences an original case of
sarcoidosis-like syndrome under nivolumab with spon-
taneous regression after treatment arrest, in the absence
of corticotherapy. It also shows that, in a patient exhibit-
ing autoimmune related effects, nivolumab arrest is
associated with a delayed and complex modulation of
PD-1 and PD-L1 expression on immune cells, which
may contribute to restore immune homeostasis. This
observation opens the question to which extent PD-1
expression in vivo controls PD-L1 expression.
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